Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trialCatia Simoes, Pau Montesinos, David Martínez‐Cuadrón et al.|Blood Advances|2021Cited by 25